Clonidine treatment of Gilles de la Tourette's syndrome

J. F. Leckman, M. T. Hardin, M. A. Riddle, J. Stevenson, S. I. Ort and D. J. Cohen
Child Study Center, Yale University School of Medicine, New Haven, CT 06510.

The safety and effectiveness of clonidine hydrochloride (3 to 5 micrograms/kg per day) were evaluated in 47 subjects with Gilles de la Tourette's syndrome, aged 7 to 48 years. Twenty-four subjects were randomly assigned to clonidine treatment and 23 to placebo. Forty subjects (21 given clonidine and 19 placebo) successfully completed the 12-week, double-blind clinical trial. Clinical ratings of tic severity improved for both groups. The magnitude of response was greater in the group receiving clonidine. Clinician-rated measures of motor tic severity, the degree to which the tics are "noticeable to others," motor tic counts from videotaped interviews, and parent-rated measures of impulsivity and hyperactivity were the most responsive to clonidine treatment. These results indicate that clonidine is more effective than placebo in reducing some of the tic and other behavioral symptoms associated with Gilles de la Tourette's syndrome.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Vetter et al.
Circulation 2008;117:2407-2423.
FULL TEXT  

Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome
Spencer et al.
J Atten Disord 2008;11:470-481.
ABSTRACT  

Literature Review: Beyond Methylphenidate: Nonstimulant Medications for Youth With ADHD
Wood et al.
J Atten Disord 2007;11:341-350.
ABSTRACT  

Gilles de la Tourette's syndrome and its impact in the UK
Stern et al.
Postgrad. Med. J. 2005;81:12-19.
ABSTRACT | FULL TEXT  

Separation Anxiety Triggered by Atypical Neuroleptic Medication in an Adolescent with Tourette's Syndrome
Becker et al.
Clinical Child Psychology and Psychiatry 2004;9:597-603.
ABSTRACT  

A placebo-controlled trial of risperidone in Tourette syndrome
Scahill et al.
Neurology 2003;60:1130-1135.
ABSTRACT | FULL TEXT  

Psychopharmacology and Aggression: II. A Meta-Analysis of Nonstimulant Medication Effects on Overt Aggression-Related Behaviors in Youth with SED
Connor et al.
Journal of Emotional and Behavioral Disorders 2003;11:157-168.
ABSTRACT  

A Double-blind Comparison of Desipramine and Placebo in Children and Adolescents With Chronic Tic Disorder and Comorbid Attention-Deficit/Hyperactivity Disorder
Spencer et al.
Arch Gen Psychiatry 2002;59:649-656.
ABSTRACT | FULL TEXT  

Height Distribution in Children With Tourette Syndrome
Zelnik et al.
J Child Neurol 2002;17:200-204.
ABSTRACT  

Treatment of ADHD in children with tics: A randomized controlled trial
Neurology 2002;58:527-536.
ABSTRACT | FULL TEXT  

A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder
Scahill et al.
Am. J. Psychiatry 2001;158:1067-1074.
ABSTRACT | FULL TEXT  

Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial
Singer et al.
Neurology 2001;56:599-604.
ABSTRACT | FULL TEXT  

Tourette syndrome, associated conditions and the complexities of treatment
Robertson
Brain 2000;123:425-462.
ABSTRACT | FULL TEXT  

Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update
Baker et al.
J Psychopharmacol 1995;9:273-280.
ABSTRACT